Overview
BPC-157 is a 15-amino acid partial sequence derived from a protein found in gastric juice. It is the most studied regenerative peptide in tissue repair. Rodent, rabbit, and non-companion-animal veterinary data across gut, tendon, ligament, muscle, and nervous tissue.
Broad spectrum. Cross species. Well characterized safety in preclinical work.
Mechanism of action
- 01Modulates nitric oxide system for vascular and tissue repair.
- 02Upregulates VEGF and growth hormone receptor expression in injured tissue.
- 03Accelerates fibroblast migration into wound sites.
- 04Drives angiogenesis and capillary formation.
- 05Protects gastric and intestinal mucosa from ulcerogenic insults.
Molecular data
Species
Dog
Preclinical extrapolation. Post-surgical tendon and ligament healing. Chronic partial tears in performance and working dogs. Inflammatory bowel disease refractory to conventional therapy.
Cat
Chronic enteropathy adjunct. Post-surgical recovery. Feline IBD support in cases refractory to steroids.
Prescribing indications
- RecoveryPrimary usePost-surgical tendon and ligament healing.
- GastrointestinalSupportedIBD refractory to conventional therapy.
- DermatologicSupportedSlow-to-heal wounds.
- NeurologicEmergingNeuropathy and nerve injury adjunct.
Dosing and administration
Starting, maintenance, and loading doses are calculated in the platform for the patient’s weight band, at the vial strength our compounding partner dispenses, and drawn to U-100 syringe units for the client’s dosing card. Any override is logged with your initials.
See the worked dose exampleScreening and safety
Screen first
History of neoplasia or an unexplained mass
Follow up
CBPI or LOAD for pain and mobility. Recheck gait and the surgical site. Measure at baseline and recheck at 4 to 6 weeks with the same measure.
Wide therapeutic window in rodent studies. No documented lethal dose. No mutagenicity or teratogenicity reported. Cancer contraindication urged in patients with active malignancy given uncertain effects on tumor angiogenesis.
Common pairings
- BPC-157 + TB-500ComplementarySee Wolverine blend.
- BPC-157 + GHK-CuComplementarySee GLOW blend.
- KPV + BPC-157CompatibleOften considered together for GI cases.
References
Related
This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.